In addition, it was shown that KRAS-mutated cancer cells induce platelet aggregation [33], a phenomenon called TCIPA (tumor cell-induced platelet aggregation) that is associated with metastasis formation and might be an emerging therapeutic target in cancer therapy [34]. Here, KRAS is linked to neoplasm.